JP2023500338A5 - - Google Patents
Info
- Publication number
- JP2023500338A5 JP2023500338A5 JP2022525915A JP2022525915A JP2023500338A5 JP 2023500338 A5 JP2023500338 A5 JP 2023500338A5 JP 2022525915 A JP2022525915 A JP 2022525915A JP 2022525915 A JP2022525915 A JP 2022525915A JP 2023500338 A5 JP2023500338 A5 JP 2023500338A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- optionally
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026033958A JP2026113477A (ja) | 2019-11-05 | 2026-03-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931065P | 2019-11-05 | 2019-11-05 | |
| US62/931,065 | 2019-11-05 | ||
| US201962943627P | 2019-12-04 | 2019-12-04 | |
| US62/943,627 | 2019-12-04 | ||
| PCT/US2020/058788 WO2021091945A1 (en) | 2019-11-05 | 2020-11-04 | Bcma-targeted car-t cell therapy of multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033958A Division JP2026113477A (ja) | 2019-11-05 | 2026-03-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500338A JP2023500338A (ja) | 2023-01-05 |
| JP2023500338A5 true JP2023500338A5 (enExample) | 2024-02-07 |
Family
ID=73598214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525915A Pending JP2023500338A (ja) | 2019-11-05 | 2020-11-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
| JP2026033958A Pending JP2026113477A (ja) | 2019-11-05 | 2026-03-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033958A Pending JP2026113477A (ja) | 2019-11-05 | 2026-03-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12522645B2 (enExample) |
| EP (1) | EP4055049A1 (enExample) |
| JP (2) | JP2023500338A (enExample) |
| KR (1) | KR20220100612A (enExample) |
| CN (1) | CN114929747A (enExample) |
| AU (1) | AU2020378263A1 (enExample) |
| BR (1) | BR112022008633A2 (enExample) |
| CA (1) | CA3159808A1 (enExample) |
| IL (1) | IL292701A (enExample) |
| JO (1) | JOP20220099A1 (enExample) |
| MX (1) | MX2022005443A (enExample) |
| PH (1) | PH12022551032A1 (enExample) |
| WO (1) | WO2021091945A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021266428A1 (en) * | 2020-05-04 | 2023-01-19 | Bio-Diagnostics Limited | A diagnostic device |
| AU2023373360A1 (en) * | 2022-11-02 | 2025-06-12 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| CN117186229B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用 |
| CA3205511A1 (en) * | 2023-04-19 | 2025-03-17 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026165530A1 (en) | 2025-02-03 | 2026-08-06 | Renagade Therapeutics Management Inc. | Hydrophilic polymer lipids for use in lipid nanoparticles |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| CA3020599A1 (en) | 2016-04-15 | 2017-10-19 | The Children's Hospital Of Philadelphia | Compositions and methods of chimeric alloantigen receptor t cells |
| CN105837693A (zh) | 2016-05-30 | 2016-08-10 | 李斯文 | 一种基于bcma的抗原嵌合受体及其制备方法和应用 |
| PL3896091T3 (pl) * | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| BR112022011964A2 (pt) | 2019-12-17 | 2022-09-06 | Shenzhen Feipeng Biological Therapy Co Ltd | Anticorpo de ligação a bcma e uso do mesmo |
| WO2022116086A1 (en) | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| IL308345A (en) | 2021-05-11 | 2024-01-01 | Janssen Biotech Inc | Methods for Minimizing Neurotoxicity Associated with Chimeric Antigen Receptor (CAR) T Cell Therapy |
| WO2023077343A1 (en) | 2021-11-04 | 2023-05-11 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| JP2024540275A (ja) | 2021-11-04 | 2024-10-31 | ヤンセン バイオテック， インク． | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照 |
| JP2025507678A (ja) | 2022-02-28 | 2025-03-21 | ヤンセン バイオテック， インク． | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 |
| AU2023373360A1 (en) | 2022-11-02 | 2025-06-12 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| CA3205511A1 (en) | 2023-04-19 | 2025-03-17 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
-
2020
- 2020-11-04 US US17/088,845 patent/US12522645B2/en active Active
- 2020-11-04 KR KR1020227018771A patent/KR20220100612A/ko active Pending
- 2020-11-04 IL IL292701A patent/IL292701A/en unknown
- 2020-11-04 WO PCT/US2020/058788 patent/WO2021091945A1/en not_active Ceased
- 2020-11-04 BR BR112022008633A patent/BR112022008633A2/pt unknown
- 2020-11-04 PH PH1/2022/551032A patent/PH12022551032A1/en unknown
- 2020-11-04 CA CA3159808A patent/CA3159808A1/en active Pending
- 2020-11-04 EP EP20812497.4A patent/EP4055049A1/en active Pending
- 2020-11-04 JP JP2022525915A patent/JP2023500338A/ja active Pending
- 2020-11-04 MX MX2022005443A patent/MX2022005443A/es unknown
- 2020-11-04 CN CN202080091870.8A patent/CN114929747A/zh active Pending
- 2020-11-04 AU AU2020378263A patent/AU2020378263A1/en active Pending
-
2022
- 2022-04-28 JO JOP/2022/0099A patent/JOP20220099A1/ar unknown
-
2025
- 2025-12-04 US US19/409,583 patent/US20260217788A1/en active Pending
-
2026
- 2026-03-04 JP JP2026033958A patent/JP2026113477A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210206828A9 (en) | Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7356970B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| US20190048085A1 (en) | Modified cells for immunotherapy | |
| CN110582488A (zh) | 具有增强功效的免疫效应细胞疗法 | |
| SG190598A1 (en) | Agent for treating disease | |
| JP2020530777A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020530306A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN110144012A (zh) | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 | |
| IL297773B1 (en) | Engineered gamma delta t-cells | |
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| EP4446342A1 (en) | Multi-specific t cell engagers comprising lrrc15 antigen-binding domain | |
| Offidani et al. | Novel experimental drugs for treatment of multiple myeloma | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CA3158985A1 (en) | Sequential anti-cd19 therapy | |
| WO2024012457A1 (zh) | 三特异性抗体及其用途 | |
| JP2021525068A5 (enExample) | ||
| JP2021525067A5 (enExample) | ||
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| WO2025195483A1 (en) | Mesothelin targetting antibodies, chimeric antigen receptors, and uses thereof | |
| RU2824391C2 (ru) | Иммунные клетки, экспрессирующие обратный универсальный химерный антигенный рецептор, для нацеливания на различные многочисленные антигены и способ их получения и применения для лечения рака, инфекций и аутоиммунных заболеваний | |
| HK40097671A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HK40097672A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) | |
| HK40109798A (en) | Guidance and navigation control proteins and method of making and using thereof |